NITD008 is a potent and selective flaviviruses inhibitor which can inhibit DENV-2 with an EC50 of 0.64 μM.
NITD008 细胞实验
Cell Line
Concentration
Treated Time
Description
References
CRFK cells
0.94 µM
24 hours
Evaluate the antiviral effect of NITD008 on FCV, results showed NITD008 significantly inhibited FCV replication
Viruses. 2019 May 30;11(6):496
Vero cells
0.67 µM
48 hours
To evaluate the in vitro antiviral activity of NITD008 against EV71, results showed that NITD008 effectively inhibited EV71 replication at a concentration of 0.67 μM.
J Virol. 2014 Oct;88(20):11915-23
Huh-7 cells
0.11 µM (EC50)
48 hours
Evaluate inhibitory effect of NITD008 on HCV, with EC50 of 0.11 μM.
Proc Natl Acad Sci U S A. 2009 Dec 1;106(48):20435-9
DENV-2 cells
0.64 µM (EC50)
48 hours
NITD008 inhibited DENV-2 in a dose-responsive manner, with an EC50 value (the compound concentration required to inhibit 50% of viral titer) of 0.64 μM.
Proc Natl Acad Sci U S A. 2009 Dec 1;106(48):20435-9
Huh7 cells
5 µM
48 hours
Used for high-throughput screening of anti-JEV compounds. NITD008 served as a positive control, with a Z' value of 0.83 at 0.3 μM, indicating the system is suitable for screening JEV inhibitors.
Antiviral Res. 2020 Oct;182:104884
Huh7 cells
0.21 µM
48 hours
Evaluate the antiviral effect of NITD008 on human norovirus replicon, results showed NITD008 significantly inhibited replicon levels
Viruses. 2019 May 30;11(6):496
RAW264.7 cells
0.91 µM
48 hours
Evaluate the antiviral effect of NITD008 on MNV, results showed NITD008 significantly inhibited MNV replication
Viruses. 2019 May 30;11(6):496
Vero cells
241 nM (GZ01/2016), 137 nM (FSS13025/2010)
48 hours
Inhibited ZIKV replication with EC50 values of 241 nM and 137 nM
Open Forum Infect Dis. 2016 Aug 30;3(4):ofw175
Huh7 cells
0.02 to 2.50 µM
72 hours
Evaluation of NITD008 inhibition on HEV genotype 1 replicon, showing EC50 of 0.03 μM, CC50>100 μM, therapeutic index>3,333
Antimicrob Agents Chemother. 2019 May 24;63(6):e00003-19
BHK-21 cells
3 µM
72 hours
To evaluate the inhibitory effect of NITD008 on eGFP-JEV reporter virus. Results showed dose-dependent inhibitory effects on both eGFP expression and viral titers, with an EC50 of 0.22 μM.
Antiviral Res. 2020 Oct;182:104884
NITD008 动物实验
Species
Animal Model
Administration
Dosage
Frequency
Description
References
C57BL/6 mice
WNV infection model
Oral gavage
10 and 25 mg/kg
Twice daily for days 1 to 6
NITD008 significantly attenuates viremia and prevents neuroinvasion, resulting in complete protection from WNV-associated mortality and morbidity.
Antiviral Res. 2015 Oct;122:39-45
AG129 mice
DENV-2 infection model
Oral gavage
25 mg/kg
Twice daily for three consecutive days
Assessed the antiviral efficacy of NITD008 in a DENV-infected mouse model, showing a significant 20-fold reduction in viremia
J Virol. 2014 Feb;88(3):1740-7
Mice
AG129 mice
Oral
3, 10, 25, 50 mg/kg
Twice daily for 3 days
Evaluate efficacy of NITD008 in DENV-infected mouse model, showing dose-dependent reduction in viremia and cytokine levels, and complete prevention of death.
Proc Natl Acad Sci U S A. 2009 Dec 1;106(48):20435-9
AG129 mice
EV71 infection model
Oral
5 mg/kg
Twice daily for 3 consecutive days
To evaluate the in vivo efficacy of NITD008 in an EV71-infected mouse model, results showed that NITD008 completely prevented clinical symptoms and death.
J Virol. 2014 Oct;88(20):11915-23
A129 mice
ZIKV infection model
Oral
50 mg/kg
Once daily for 5 days
Significantly reduced viremia and 50% survival rate
搜索
